Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer
Galina Semenova(University of California, Los Angeles), John K. Lee(University of Washington)
Cited by 0
Related Papers
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
|Nature Communications|2023|118